Advertisement

Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-Based Nutrition Practice Guideline

      Abstract

      The Academy of Nutrition and Dietetics Evidence Analysis Center conducted a systematic review of the literature to develop an evidence-based practice guideline for primary nutrition issues in cystic fibrosis (CF). This guideline is designed to complement and build upon existing evidence-based CF nutrition guidelines. The objective of this guideline was to provide recommendations for registered dietitian nutritionists in the United States delivering medical nutrition therapy to individuals with CF and their families that fill gaps in current evidence-based guidelines on topics that are crucial in order to improve health and prevent disease progression. This guideline provides 28 nutrition recommendations to guide medical nutrition therapy, including nutrition screening, nutrition assessment, and dietary intake. For topics outside the scope of this guideline, practitioners are referred to external, evidence-based recommendations. The CF landscape is evolving rapidly with breakthroughs in cystic fibrosis transmembrane regulator modulators changing CF at a cellular level. Medical nutrition therapy for individuals with CF from infancy through advanced age requires novel and individualized approaches. The Academy Evidence Analysis Library CF guidelines provide a framework for expanding upon current knowledge to determine effective nutrition strategies for individuals with CF through long and healthy futures.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Academy of Nutrition and Dietetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Saxby N.
        • Painter C.
        • Kench A.
        • King S.
        • Crowder T.
        • van der Haak N.
        • Australian and New Zealand Cystic Fibrosis Nutrition Guideline Authorship Group
        Nutrition Guidelines for Cystic Fibrosis in Australia and New Zealand.
        Thoracic Society of Australia and New Zealand, Sydney2017
        • Turck D.
        • Braegger C.P.
        • Colombo C.
        • et al.
        ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis.
        Clin Nutr. 2016; 35: 557-577
        • Borowitz D.
        • Baker R.D.
        • Stallings V.
        Consensus report on nutrition for pediatric patients with cystic fibrosis.
        J Pediatr Gastroenterol Nutr. 2002; 35: 246-259
        • Aris R.M.
        • Merkel P.A.
        • Bachrach L.K.
        • et al.
        Guide to bone health and disease in cystic fibrosis.
        J Clin Endocrinol Metab. 2005; 90: 1888-1896
        • Stallings V.
        • Stark L.
        • Robinson K.
        • Feranchak A.
        • Quinton H.
        Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: Results of a systematic review.
        J Am Diet Assoc. 2008; 108: 832-839
        • Borowitz D.
        • Robinson K.A.
        • Rosenfeld M.
        • et al.
        Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.
        J Pediatr. 2009; 155: S73-S93
        • Tangpricha V.
        • Kelly A.
        • Stephenson A.
        • et al.
        An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: Evidence-based recommendations from the Cystic Fibrosis Foundation.
        J Clin Endocrinol Metab. 2012; 97: 1082-1093
        • Schwarzenberg S.J.
        • Hempstead S.E.
        • McDonald C.M.
        • et al.
        Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines.
        J Cyst Fibros. 2016; 15: 724-735
        • Hadjiliadis D.
        • Khoruts A.
        • Zauber A.G.
        • Hempstead S.E.
        • Maisonneuve P.
        • Lowenfels A.B.
        Cystic Fibrosis colorectal cancer screening consensus recommendations.
        Gastroenterology. 2018; 154: 736-745.e714
        • Corey M.
        • McLaughlin F.J.
        • Williams M.
        • Levison H.
        A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto.
        J Clin Epidemiol. 1988; 41: 583-591
        • Sutherland R.
        • Katz T.
        • Liu V.
        • et al.
        Dietary intake of energy-dense, nutrient-poor and nutrient-dense food sources in children with cystic fibrosis.
        J Cyst Fibros. 2018; 17: 804-810
        • Calvo-Lerma J.
        • Hulst J.
        • Boon M.
        • et al.
        The relative contribution of food groups to macronutrient intake in children with cystic fibrosis: A European Multicenter Assessment.
        J Acad Nutr Diet. 2019; 119: 1305-1319
        • Handu D.
        • Moloney L.
        • Wolfram T.
        • Ziegler P.
        • Acosta A.
        • Steiber A.
        Academy of Nutrition and Dietetics methodology for conducting systematic reviews for the Evidence Analysis Library.
        J Acad Nutr Diet. 2016; 116: 311-318
        • Papoutsakis C.
        • Moloney L.
        • Sinley R.C.
        • Acosta A.
        • Handu D.
        • Steiber A.L.
        Academy of Nutrition and Dietetics methodology for developing evidence-based nutrition practice guidelines.
        J Acad Nutr Diet. 2017; 117: 794-804
        • Academy of Nutrition and Dietetics Evidence Analysis Library
        Evidence Analysis Library Cystic Fibrosis Project.
        (Published 2019. Accessed February 5, 2020)
        • AGREE Next Steps Consortium
        The AGREE II Instrument (electronic version).
        (Published 2017. Accessed February 3, 2020)
        • Rozga M.
        • Handu D.
        Nutrition Care for patients with cystic fibrosis: An Evidence Analysis Center scoping review.
        J Acad Nutr Diet. 2019; 119: 137-151.e131
        • Rozga M.
        Nutritional assessment and dietary interventions in patients with cystic fibrosis. PROSPERO 2018 CRD42018097373. National Institute for Health Research.
        (Published 2018. Accessed December 3, 2019)
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.
        J Clin Epidemiol. 2009; 62: 1006-1012
        • Academy of Nutrition and Dietetics Evidence Analysis Library
        Evidence Analysis Manual: Steps in the Academy Evidence Analysis Process: A Systematic Review and Guideline Manual.
        Academy of Nutrition and Dietetics, Chicago, IL2016
        • Guyatt G.
        • Oxman A.D.
        • Akl E.A.
        • et al.
        GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
        J Clin Epidemiol. 2011; 64: 383-394
        • GRADEpro GDT
        GRADEpro Guideline Development Tool [computer program].
        McMaster University, Hamilton, Ontario, Canada2015
        • Moberg J.
        • Oxman A.D.
        • Rosenbaum S.
        • et al.
        The GRADE Evidence to Decision (EtD) framework for health system and public health decisions.
        Health Res Policy Syst. 2018; 16: 45
        • Alonso-Coello P.
        • Schunemann H.J.
        • Moberg J.
        • et al.
        GRADE Evidence to Decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 1: Introduction.
        BMJ. 2016; 353: i2016
        • American Academy of Pediatrics Steering Committee on Quality Improvement and Management
        Classifying recommendations for clinical practice guidelines.
        Pediatrics. 2004; 114: 874-877s
        • Cystic Fibrosis Foundation
        Your CF Care Team. Cystic Fibrosis Foundation.
        https://www.cff.org/Care/Your-CF-Care-Team/
        Date accessed: October 15, 2019
        • Ramirez I.
        • Filbrun A.
        • Hasan A.
        • Kidwell K.M.
        • Nasr S.Z.
        Improving nutritional status in a pediatric cystic fibrosis center.
        Pediatr Pulmonol. 2015; 50: 544-551
        • Stark L.J.
        • Opipari-Arrigan L.
        • Quittner A.L.
        • Bean J.
        • Powers S.W.
        The effects of an intensive behavior and nutrition intervention compared to standard of care on weight outcomes in CF.
        Pediatr Pulmonol. 2011; 46: 31-35
        • Savant A.P.
        • Britton L.J.
        • Petren K.
        • McColley S.A.
        • Gutierrez H.H.
        Sustained improvement in nutritional outcomes at two paediatric cystic fibrosis centres after quality improvement collaboratives.
        BMJ Qual Saf. 2014; 23: 81-89
        • Academy of Nutrition and Dietetics Evidence Analysis Library
        In individuals with CF, what is the longitudinal relationship (at least 3 months) between weight and growth parameters and FEV1? Academy of Nutrition and Dietetics. Cystic Fibrosis Systematic Review web site.
        (Updated August 2019. Accessed September 10, 2019)
        • Darrah R.
        • Nelson R.
        • Damato E.G.
        • Decker M.
        • Matthews A.
        • Hodges C.A.
        Growth deficiency in cystic fibrosis is observable at birth and predictive of early pulmonary function.
        Biol Res Nurs. 2016; 18: 498-504
        • Emerson J.
        • Rosenfeld M.
        • McNamara S.
        • Ramsey B.
        • Gibson R.L.
        Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
        Pediatr Pulmonol. 2002; 34: 91-100
        • Goss C.H.
        • Sykes J.
        • Stanojevic S.
        • et al.
        Comparison of nutrition and lung function outcomes in patients with cystic fibrosis living in Canada and the United States.
        Am J Respir Crit Care Med. 2018; 197: 768-775
        • Keller B.M.
        • Aebischer C.C.
        • Kraemer R.
        • Schoni M.H.
        Growth in prepubertal children with cystic fibrosis, homozygous for the Delta F508 mutation.
        J Cyst Fibros. 2003; 2: 76-83
        • Konstan M.W.
        • Morgan W.J.
        • Butler S.M.
        • et al.
        Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.
        J Pediatr. 2007; 151: 134-139.e131
        • Lai H.J.
        • Shoff S.M.
        • Farrell P.M.
        • Wisconsin Cystic Fibrosis Neonatal Screening Group
        Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis.
        Pediatrics. 2009; 123: 714-722
        • Machogu E.
        • Cao Y.
        • Miller T.
        • et al.
        Comparison of WHO and CDC growth charts in predicting pulmonary outcomes in cystic fibrosis.
        J Pediatr Gastroenterol Nutr. 2015; 60: 378-383
        • McPhail G.L.
        • Acton J.D.
        • Fenchel M.C.
        • Amin R.S.
        • Seid M.
        Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use.
        J Pediatr. 2008; 153: 752-757
        • Sanders D.B.
        • Li Z.
        • Laxova A.
        • et al.
        Risk factors for the progression of cystic fibrosis lung disease throughout childhood.
        Ann Am Thorac Soc. 2014; 11: 63-72
        • Sanders D.B.
        • Fink A.
        • Mayer-Hamblett N.
        • et al.
        Early life growth trajectories in cystic fibrosis are associated with pulmonary function at age 6 years.
        J Pediatr. 2015; 167: 1081-1088.e1081
        • Sanders D.B.
        • Emerson J.
        • Ren C.L.
        • et al.
        Early childhood risk factors for decreased FEV1 at age six to seven years in young children with cystic fibrosis.
        Ann Am Thorac Soc. 2015; 12: 1170-1176
        • Sanders D.B.
        • Zhang Z.
        • Farrell P.M.
        • Lai H.J.
        • Wisconsin CF Neonatal Screening Group
        Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis.
        J Cyst Fibros. 2018; 17: 528-535
        • Usatin D.
        • Yen E.H.
        • McDonald C.
        • Asfour F.
        • Pohl J.
        • Robson J.
        Differences between WHO and CDC early growth measurements in the assessment of cystic fibrosis clinical outcomes.
        J Cyst Fibros. 2017; 16: 503-509
        • Welsh L.
        • Robertson C.F.
        • Ranganathan S.C.
        Increased rate of lung function decline in Australian adolescents with cystic fibrosis.
        Pediatr Pulmonol. 2014; 49: 873-877
        • Woestenenk J.W.
        • Stellato R.K.
        • Terheggen-Lagro S.W.
        • van der Ent C.K.
        • Houwen R.H.J.
        The relationship between body growth and pulmonary function in children with cystic fibrosis.
        Acta Paediatr. 2014; 103: 162-167
        • Yen E.H.
        • Quinton H.
        • Borowitz D.
        Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis.
        J Pediatr. 2013; 162: 530-535.e531
        • Amadori A.
        • Antonelli A.
        • Balteri I.
        • Schreiber A.
        • Bugiani M.
        • De Rose V.
        Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.
        Respir Med. 2009; 103: 407-413
        • Ramos K.J.
        • Quon B.S.
        • Heltshe S.L.
        • et al.
        Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 <30% of Predicted in the United States.
        Chest. 2017; 151: 1320-1328
        • George P.M.
        • Banya W.
        • Pareek N.
        • et al.
        Improved survival at low lung function in cystic fibrosis: Cohort study from 1990 to 2007.
        BMJ. 2011; 342: d1008
        • Chamnan P.
        • Shine B.S.F.
        • Haworth C.S.
        • Bilton D.
        • Adler A.I.
        Diabetes as a determinant of mortality in cystic fibrosis.
        Diabetes Care. 2010; 33: 311-316
        • Stephenson A.L.
        • Tom M.
        • Berthiaume Y.
        • et al.
        A contemporary survival analysis of individuals with cystic fibrosis: A cohort study.
        Eur Respir J. 2015; 45: 670-679
        • Vieni G.
        • Faraci S.
        • Collura M.
        • et al.
        Stunting is an independent predictor of mortality in patients with cystic fibrosis.
        Clin Nutr. 2013; 32: 382-385
        • McColley S.A.
        • Schechter M.S.
        • Morgan W.J.
        • Pasta D.J.
        • Craib M.L.
        • Konstan M.W.
        Risk factors for mortality before age 18 years in cystic fibrosis.
        Pediatr Pulmonol. 2017; 52: 909-915
        • Cystic Fibrosis Foundation Patient Registry
        2017 Annual Data Report.
        Cystic Fibrosis Foundation, Bethesda, MD2018
        • Grummer-Strawn L.M.
        • Reinold C.
        • Krebs N.F.
        Use of World Health Organization and CDC growth charts for children aged 0-59 months in the United States.
        MMWR Recomm Rep. 2010; 59: 1-15
        • Zhang Z.
        • Shoff S.M.
        • Lai H.J.
        Comparing the use of Centers for Disease Control and Prevention and World Health Organization growth charts in children with cystic fibrosis through 2 years of age.
        J Pediatr. 2015; 167: 1089-1095
        • Cystic Fibrosis Foundation
        Nutritional basics.
        • Hollander F.M.
        • van Pierre D.D.
        • de Roos N.M.
        • van de Graaf E.A.
        • Iestra J.A.
        Effects of nutritional status and dietetic interventions on survival in cystic fibrosis patients before and after lung transplantation.
        J Cyst Fibros. 2014; 13: 212-218
        • King S.J.
        • Nyulasi I.B.
        • Strauss B.J.G.
        • Kotsimbos T.
        • Bailey M.
        • Wilson J.W.
        Fat-free mass depletion in cystic fibrosis: Associated with lung disease severity but poorly detected by body mass index.
        Nutrition. 2010; 26: 753-759
        • Ledger S.J.
        • Owen E.
        • Prasad S.A.
        • Goldman A.
        • Willams J.
        • Aurora P.
        A pilot outreach physiotherapy and dietetic quality improvement initiative reduces IV antibiotic requirements in children with moderate-severe cystic fibrosis.
        J Cyst Fibros. 2013; 12: 766-772
        • Academy of Nutrition and Dietetics Evidence Analysis Library
        In individuals with CF, what is the validity and reliability or nutrition assessment methods compared to reference standards, as measured by validity and/or reliability studies? Academy of Nutrition and Dietetics Evidence Analysis Library.
        (Published 2019. Accessed September 26, 2019)
        • Academy of Nutrition and Dietetics Evidence Analysis Library
        In individuals with CF, what is the relationship between nutrition parameters and hard outcomes?.
        (Published 2019. Accessed September 25, 2019)
        • Centers for Disease Control and Prevention
        Defining childhood obesity.
        (Published 2019. Updated July 3, 2018. Accessed November 27, 2019)
      1. EBMcalc. An educational medical reference.
        (Published 2019. Accessed January 9, 2020)
        • Tanner J.M.
        • Goldstein H.
        • Whitehouse R.H.
        Standards for children's height at ages 2-9 years allowing for heights of parents.
        Arch Dis Child. 1970; 45: 755-762
        • Centers for Disease Control and Prevention
        Defining adult overweight and obesity.
        (Published 2019. Updated April 11, 2017. Accessed November 27, 2019)
        • Centers for Disease Control and Prevention
        Getting your cholesterol checked.
        (Published 2019. Accessed September 2019)
        • American Academy of Pediatrics
        2016 Recommendations for Preventive Pediatric Health Care.
        Pediatrics. 2016; : 137
        • Academy of Nutrition and Dietetics
        Pediatric Nutrition Focused Physical Exam Pocket Guide.
        Academy of Nutrition and Dietetics, Chicago, IL2016
        • Cystic Fibrosis Foundation
        Our mission.
        (Published 2019. Accessed September 25, 2019)
        • Borowitz D.
        • Lubarsky B.
        • Wilschanski M.
        • et al.
        Nutritional status improved in cystic fibrosis patients with the G551D mutation after treatment with ivacaftor.
        Dig Dis Sci. 2016; 61: 198-207
        • Davies J.C.
        • Wainwright C.E.
        • Canny G.J.
        • et al.
        Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
        Am J Respir Criti Care Med. 2013; 187: 1219-1225
        • Konstan M.W.
        • Plant B.J.
        • Elborn J.S.
        • et al.
        Efficacy response in CF patients treated with ivacaftor: Post-hoc analysis.
        Pediatr Pulmonol. 2015; 50: 447-455
        • Ramsey B.W.
        • Davies J.
        • McElvaney N.G.
        • et al.
        A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
        N Engl J Med. 2011; 365: 1663-1672
        • Stalvey M.S.
        • Pace J.
        • Nikniar M.
        • et al.
        Growth in prepubertal children with cystic fibrosis treated with ivacaftor.
        Pediatrics. 2017; 139 (44-44)
        • De Boeck K.
        • Munck A.
        • Walker S.
        • et al.
        Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
        J Cyst Fibros. 2014; 13: 674-680
        • Edgeworth D.
        • Keating D.
        • Ellis M.
        • et al.
        Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: A double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.
        Clin Sci (Lond). 2017; 131: 2037-2045
        • Moss R.B.
        • Flume P.A.
        • Elborn J.S.
        • et al.
        Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trial.
        Lancet Respir Med. 2015; 3: 524-533
        • Ratjen F.
        • Hug C.
        • Marigowda G.
        • et al.
        Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: A randomised, placebo-controlled phase 3 trial.
        Lancet Respir Med. 2017; 5: 557-567
        • Elborn J.S.
        • Ramsey B.W.
        • Boyle M.P.
        • et al.
        Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: A pooled analysis.
        Lancet Respir Med. 2016; 4: 617-626
        • Rowe S.M.
        • McColley S.A.
        • Rietschel E.
        • et al.
        Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR.
        Ann Am Thorac Soc. 2017; 14: 213-219
        • Wainwright C.E.
        • Elborn J.S.
        • Ramsey B.W.
        • et al.
        Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR.
        N Engl J Med. 2015; 373: 220-231
        • Taylor-Cousar J.L.
        • Munck A.
        • McKone E.F.
        • et al.
        Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del.
        N Engl J Med. 2017; 377: 2013-2023
        • Stallings V.A.
        • Sainath N.
        • Oberle M.
        • Bertolaso C.
        • Schall J.I.
        Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations.
        J Pediatr. 2018; 201: 229-237.e224
        • Middleton P.G.
        • Mall M.A.
        • Drevinek P.
        • et al.
        Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele.
        N Engl J Med. 2019; 381: 1809-1819
        • Heijerman H.G.M.
        • McKone E.F.
        • Downey D.G.
        • et al.
        Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial.
        Lancet. 2019; 394: 1940-1948
      2. Vertex Pharmaceuticals Incorporated. Prescribing information. TRIKAFTA (elexaccaftor/tezacaftor/ivacaftor; ivacaftor) tablets. Table 4: Pharmacokinetic parameters of TRIKAFTA components. Vertex Pharmaceuticals Incorporated; 2019.

        • Davies J.C.
        • Cunningham S.
        • Harris W.T.
        • et al.
        Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study.
        Lancet Respir Med. 2016; 4: 107-115
        • Rosenfeld M.
        • Cunningham S.
        • Harris W.T.
        • et al.
        An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).
        J Cyst Fibros. 2019; 18: 838-843
        • Cystic Fibrosis Foundation
        Clinical Considerations: TRIKAFTA™.
        Cystic Fibrosis Foundation, Bethesda, MD2019
        • Moudiou T.
        • Galli-Tsinopoulou A.
        • Vamvakoudis E.
        • Nousia-Arvanitakis S.
        Resting energy expenditure in cystic fibrosis as an indicator of disease severity.
        J Cyst Fibros. 2007; 6: 131-136
        • Moudiou T.
        • Galli-Tsinopoulou A.
        • Nousia-Arvanitakis S.
        Effect of exocrine pancreatic function on resting energy expenditure in cystic fibrosis.
        Acta Paediatr. 2007; 96: 1521-1525
        • Trabulsi J.
        • Ittenbach R.F.
        • Schall J.I.
        • et al.
        Evaluation of formulas for calculating total energy requirements of preadolescent children with cystic fibrosis.
        Am J Clin Nutr. 2007; 85: 144-151
        • Hollander F.M.
        • Kok A.
        • de Roos N.M.
        • Belle-van Meerkerk G.
        • van de Graaf E.A.
        Prediction equations underestimate resting energy expenditure in patients with end-stage cystic fibrosis.
        Nutr Clin Pract. 2017; 32: 116-121
        • Brooks M.J.
        • Melnik G.
        The refeeding syndrome: An approach to understanding its complications and preventing its occurrence.
        Pharmacotherapy. 1995; 15: 713-726
        • Alpers D.H.
        • Klein S.
        Refeeding the malnourished patient.
        Curr Opin Gastroenterol. 1999; 15: 151-153
        • Marik P.E.
        • Bedigian M.K.
        Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study.
        Arch Surg. 1996; 131: 1043-1047
        • Afzal N.A.
        • Addai S.
        • Fagbemi A.
        • Murch S.
        • Thomson M.
        • Heuschkel R.
        Refeeding syndrome with enteral nutrition in children: A case report, literature review and clinical guidelines.
        Clin Nutr. 2002; 21: 515-520
        • Solomon S.M.
        • Kirby D.F.
        The refeeding syndrome: A review.
        JPEN J Parenter Enteral Nutr. 1990; 14: 90-97
        • Calella P.
        • Valerio G.
        • Thomas M.
        • et al.
        Association between body composition and pulmonary function in children and young people with cystic fibrosis.
        Nutrition. 2018; 48: 73-76
        • Pedreira C.C.
        • Robert R.G.D.
        • Dalton V.
        • et al.
        Association of body composition and lung function in children with cystic fibrosis.
        Pediatr Pulmonol. 2005; 39: 276-280
        • Sheikh S.
        • Zemel B.S.
        • Stallings V.A.
        • Rubenstein R.C.
        • Kelly A.
        Body composition and pulmonary function in cystic fibrosis.
        Front Pediatr. 2014; 2: 33
        • Ionescu A.A.
        • Nixon L.S.
        • Luzio S.
        • et al.
        Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis.
        Am J Respir Criti Care Med. 2002; 165: 495-500
        • Olveira G.
        • Olveira C.
        • Gaspar I.
        • et al.
        Fat-free mass depletion and inflammation in patients with bronchiectasis.
        J Acad Nutr Diet. 2012; 112: 1999-2006
        • Engelen M.P.K.J.
        • Schroder R.
        • Van der Hoorn K.
        • Deutz N.E.P.
        • Com G.
        Use of body mass index percentile to identify fat-free mass depletion in children with cystic fibrosis.
        Clin Nutr. 2012; 31: 927-933
        • Ionescu A.A.
        • Evans W.D.
        • Pettit R.J.
        • Nixon L.S.
        • Stone M.D.
        • Shale D.J.
        Hidden depletion of fat-free mass and bone mineral density in adults with cystic fibrosis.
        Chest. 2003; 124: 2220-2228
        • Abramowitz M.K.
        • Hall C.B.
        • Amodu A.
        • Sharma D.
        • Androga L.
        • Hawkins M.
        Muscle mass, BMI, and mortality among adults in the United States: A population-based cohort study.
        PLoS One. 2018; 13e0194697
        • Wells G.D.
        • Heale L.
        • Schneiderman J.E.
        • et al.
        Assessment of body composition in pediatric patients with cystic fibrosis.
        Pediatr Pulmonol. 2008; 43: 1025-1032
        • Williams J.E.
        • Wells J.C.
        • Benden C.
        • et al.
        Body composition assessed by the 4-component model and association with lung function in 6-12-y-old children with cystic fibrosis.
        Am J Clin Nutr. 2010; 92: 1332-1343
        • Puiman P.J.
        • Francis P.
        • Buntain H.
        • Wainwright C.
        • Masters B.
        • Davies P.S.W.
        Total body water in children with cystic fibrosis using bioelectrical impedance.
        J Cyst Fibros. 2004; 3: 243-247
        • Calella P.
        • Valerio G.
        • Brodlie M.
        • Taylor J.
        • Donini L.M.
        • Siervo M.
        Tools and methods used for the assessment of body composition in patients with cystic fibrosis: A systematic review.
        Nutr Clin Pract. 2019; 34: 701-714
        • Sheean P.
        • Gonzalez M.C.
        • Prado C.M.
        • McKeever L.
        • Hall A.M.
        • Braunschweig C.A.
        American Society for Parenteral and Enteral Nutrition clinical guidelines: The validity of body composition assessment in clinical populations.
        JPEN J Parenter Enteral Nutr. 2020; 44: 12-43
        • Charatsi A.M.
        • Dusser P.
        • Freund R.
        • et al.
        Bioelectrical impedance in young patients with cystic fibrosis: Validation of a specific equation and clinical relevance.
        J Cyst Fibros. 2016; 15: 825-833
        • Hollander F.M.
        • De Roos N.M.
        • De Vries J.H.M.
        • Van Berkhout F.T.
        Assessment of nutritional status in adult patients with cystic fibrosis: Whole-body bioimpedance vs body mass index, skinfolds, and leg-to-leg bioimpedance.
        J Am Diet Assoc. 2005; 105: 549-555
        • King S.
        • Wilson J.
        • Kotsimbos T.
        • Bailey M.
        • Nyulasi I.
        Body composition assessment in adults with cystic fibrosis: Comparison of dual-energy X-ray absorptiometry with skinfolds and bioelectrical impedance analysis.
        Nutrition. 2005; 21: 1087-1094
        • Becker P.
        • Carney L.N.
        • Corkins M.R.
        • et al.
        Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: Indicators recommended for the identification and documentation of pediatric malnutrition (undernutrition).
        Nutr Clin Pract. 2015; 30: 147-161
        • Addo O.Y.
        • Himes J.H.
        Reference curves for triceps and subscapular skinfold thicknesses in US children and adolescents.
        Am J Clin Nutr. 2010; 91: 635-642
        • World Health Organization
        Child growth standards, arm circumference-for-age.
        (Published 2020. Accessed January 13, 2020)
        • World Health Organization
        Child growth standards, subscapular skinfold-for-age.
        (Published 2020. Accessed January 13, 2020)
        • Schmidt S.C.
        • Bosy-Westphal A.
        • Niessner C.
        • Woll A.
        Representative body composition percentiles from bioelectrical impedance analyses among children and adolescents. The MoMo study.
        Clin Nutr. 2019; 38: 2712-2720
        • Mattiello R.
        • Amaral M.A.
        • Mundstock E.
        • Ziegelmann P.K.
        Reference values for the phase angle of the electrical bioimpedance: Systematic review and meta-analysis involving more than 250,000 subjects.
        Clin Nutr. 2020; 39: 1411-1417
        • Kuchnia A.
        • Earthman C.
        • Teigen L.
        • et al.
        Evaluation of bioelectrical impedance analysis in critically ill patients: Results of a multicenter prospective study.
        JPEN J Parenter Enteral Nutr. 2017; 41: 1131-1138
        • Marquette M.
        • Haworth C.S.
        Bone health and disease in cystic fibrosis.
        Paediatr Respir Rev. 2016; 20: 2-5
        • Sermet-Gaudelus I.
        • Bianchi M.L.
        • Garabedian M.
        • et al.
        European cystic fibrosis bone mineralisation guidelines.
        J Cyst Fibros. 2011; 10: S16-S23
        • Padula L.
        • Reid E.
        • Hanna M.
        • Mascarenhas M.
        • Kelly A.
        • Mallowe A.
        DXA Screening Guidelines for CF Patients at CHOP.
        Children's Hospital of Pennsylvania, Philadelphia2017
        • Kyle U.G.
        • Earthman C.P.
        • Pichard C.
        • Coss-Bu J.A.
        Body composition during growth in children: Limitations and perspectives of bioelectrical impedance analysis.
        Eur J Clin Nutr. 2015; 69: 1298-1305
        • Moran A.
        • Pillay K.
        • Becker D.
        • Granados A.
        • Hameed S.
        • Acerini C.L.
        ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents.
        Pediatr Diabetes. 2018; 19: 64-74
        • Rana M.
        • Wong-See D.
        • Katz T.
        • et al.
        Fat-soluble vitamin deficiency in children and adolescents with cystic fibrosis.
        J Clin Pathol. 2014; 67: 605-608
        • McCauley L.A.
        • Thomas W.
        • Laguna T.A.
        • Regelmann W.E.
        • Moran A.
        • Polgreen L.E.
        Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis.
        Ann Am Thorac Soc. 2014; 11: 198-204
        • Oregon State University Linus Pauling Institute
        Micronutrient Information Center.
        (Published 2019. Accessed December 2, 2019)
        • Rhodes B.
        • Nash E.F.
        • Tullis E.
        • et al.
        Prevalence of dyslipidemia in adults with cystic fibrosis.
        J Cyst Fibros. 2010; 9: 24-28
        • Alves C.
        • Lima D.
        • Cardeal M.
        • Santana A.
        Dyslipidemia in racially admixtured children with cystic fibrosis.
        Indian J Endocrinol Metabol. 2012; 16: 585-588
        • Figueroa V.
        • Milla C.
        • Parks E.J.
        • Schwarzenberg S.J.
        • Moran A.
        Abnormal lipid concentrations in cystic fibrosis.
        Am J Clin Nutr. 2002; 75: 1005-1011
        • Ollero M.
        • Astarita G.
        • Guerrera I.C.
        • et al.
        Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients.
        J Lipid Res. 2011; 52: 1011-1022
        • Kopin L.
        • Lowenstein C.
        Dyslipidemia.
        Ann Intern Med. 2017; 167 (Itc81-itc96)
        • Poore S.
        • Berry B.
        • Eidson D.
        • McKie K.T.
        • Harris R.A.
        Evidence of vascular endothelial dysfunction in young patients with cystic fibrosis.
        Chest. 2013; 143: 939-945
        • Cross C.E.
        • Reverri E.J.
        • Morrissey B.M.
        Joining the crowd: Cystic fibrosis and cardiovascular disease risk factors.
        Chest. 2013; 143: 882-884
        • Skolnik K.
        • Levy R.D.
        • Wilcox P.G.
        • Quon B.S.
        Coronary artery disease in cystic fibrosis: An emerging concern?.
        J Cyst Fibros. 2016; 15: e70-e71
        • Maqbool A.
        • Schall J.I.
        • Garcia-Espana J.F.
        • Zemel B.S.
        • Strandvik B.
        • Stallings V.A.
        Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis.
        J Pediatr Gastroenterol Nutr. 2008; 47: 635-644
        • Bellissimo M.P.
        • Zhang I.
        • Ivie E.A.
        • et al.
        Visceral adipose tissue is associated with poor diet quality and higher fasting glucose in adults with cystic fibrosis.
        J Cyst Fibros. 2019; 18: 430-435
        • Armaghanian N.
        • Atkinson F.
        • Taylor N.
        • et al.
        Dietary intake in cystic fibrosis and its role in glucose metabolism.
        Clin Nutr. 2020; 39: 2495-2500
        • Rodriguez-Monforte M.
        • Sanchez E.
        • Barrio F.
        • Costa B.
        • Flores-Mateo G.
        Metabolic syndrome and dietary patterns: A systematic review and meta-analysis of observational studies.
        Eur J Nutr. 2017; 56: 925-947
        • Casas R.
        • Castro-Barquero S.
        • Estruch R.
        • Sacanella E.
        Nutrition and cardiovascular health.
        Int J Mol Sci. 2018; 19
        • Grosso G.
        • Bella F.
        • Godos J.
        • et al.
        Possible role of diet in cancer: Systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk.
        Nutr Rev. 2017; 75: 405-419
        • Hosseini B.
        • Berthon B.S.
        • Saedisomeolia A.
        • et al.
        Effects of fruit and vegetable consumption on inflammatory biomarkers and immune cell populations: A systematic literature review and meta-analysis.
        Am J Clin Nutr. 2018; 108: 136-155
        • US Department of Health and Human Services and US Department of Agriculture
        2015–2020 Dietary Guidelines for Americans. 8th ed.
        (Published December 2015. Accessed April 2, 2020)
        • Widmer R.J.
        • Flammer A.J.
        • Lerman L.O.
        • Lerman A.
        The Mediterranean diet, its components, and cardiovascular disease.
        Am J Med. 2015; 128: 229-238
        • Soltani S.
        • Jayedi A.
        • Shab-Bidar S.
        • Becerra-Tomas N.
        • Salas-Salvado J.
        Adherence to the Mediterranean diet in relation to all-cause mortality: A systematic review and dose-response meta-analysis of prospective cohort studies.
        Adv Nutr. 2019; 10: 1029-1039
        • Becerra-Tomás N.
        • Blanco Mejia S.
        • Viguiliouk E.
        • et al.
        Mediterranean diet, cardiovascular disease and mortality in diabetes: A systematic review and meta-analysis of prospective cohort studies and randomized clinical trials.
        Crit Rev Food Sci Nutr. 2020; 60: 1207-1227
        • Rosato V.
        • Temple N.J.
        • La Vecchia C.
        • Castellan G.
        • Tavani A.
        • Guercio V.
        Mediterranean diet and cardiovascular disease: A systematic review and meta-analysis of observational studies.
        Eur J Nutr. 2019; 58: 173-191
        • Rees K.
        • Takeda A.
        • Martin N.
        • et al.
        Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease.
        Cochrane Database Syst Rev. 2019; 3: Cd009825
        • Esposito K.
        • Maiorino M.I.
        • Bellastella G.
        • Chiodini P.
        • Panagiotakos D.
        • Giugliano D.
        A journey into a Mediterranean diet and type 2 diabetes: A systematic review with meta-analyses.
        BMJ Open. 2015; 5e008222
        • Ciofu O.
        • Lykkesfeldt J.
        Antioxidant supplementation for lung disease in cystic fibrosis.
        Cochrane Database Syst Rev. 2014; : CD007020
        • Sagel S.D.
        • Sontag M.K.
        • Anthony M.M.
        • Emmett P.
        • Papas K.A.
        Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis.
        J Cyst Fibros. 2011; 10: 31-36
        • Sagel S.D.
        • Khan U.
        • Jain R.
        • et al.
        Effects of an antioxidant-enriched multivitamin in cystic fibrosis: Randomized, controlled, multicenter trial.
        Am J Respir Crit Care Med. 2018;
        • Shamseer L.
        • Adams D.
        • Brown N.
        • Johnson J.A.
        • Vohra S.
        Antioxidant micronutrients for lung disease in cystic fibrosis.
        Cochrane Database Syst Rev. 2010; 12: CD007020
        • Kayani K.
        • Mohammed R.
        • Mohiaddin H.
        Cystic Fibrosis-related diabetes.
        Front Endocrinol. 2018; 9: 20
        • Panagopoulou P.
        • Fotoulaki M.
        • Nikolaou A.
        • Nousia-Arvanitakis S.
        Prevalence of malnutrition and obesity among cystic fibrosis patients.
        Pediatr Int. 2014; 56: 89-94
        • Hanna R.M.
        • Weiner D.J.
        Overweight and obesity in patients with cystic fibrosis: A center-based analysis.
        Pediatr Pulmonol. 2015; 50: 35-41
        • Stephenson A.L.
        • Mannik L.A.
        • Walsh S.
        • et al.
        Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: A population-based cohort study.
        Am J Clin Nutr. 2013; 97: 872-877
        • Alvarez J.A.
        • Ziegler T.R.
        • Millson E.C.
        • Stecenko A.A.
        Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity.
        Nutrition. 2016; 32: 447-452
        • Forte G.C.
        • Pereira J.S.
        • Drehmer M.
        • Simon M.I.
        Anthropometric and dietary intake indicators as predictors of pulmonary function in cystic fibrosis patients.
        J Bras Pneumol. 2012; 38: 470-476
        • Moen I.E.
        • Nilsson K.
        • Andersson A.
        • et al.
        Dietary intake and nutritional status in a Scandinavian adult cystic fibrosis-population compared with recommendations.
        Food Nutr Res. 2011; 55
        • Gordon C.M.
        • Anderson E.J.
        • Herlyn K.
        • et al.
        Nutrient status of adults with cystic fibrosis.
        J Am Diet Assoc. 2007; 107: 2114-2119
        • White H.
        • Wolfe S.P.
        • Foy J.
        • Morton A.
        • Conway S.P.
        • Brownlee K.B.
        Nutritional intake and status in children with cystic fibrosis: Does age matter?.
        J Pediatr Gastroenterol Nutr. 2007; 44: 116-123
        • Olveira G.
        • Dorado A.
        • Olveira C.
        • et al.
        Serum phospholipid fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis.
        Br J Nutr. 2006; 96: 343-349
        • Declercq D.
        • Van Biervliet S.
        • Robberecht E.
        Nutrition and pancreatic enzyme intake in patients with cystic fibrosis with distal intestinal obstruction syndrome.
        Nutr Clin Pract. 2015; 30: 134-137
        • Proesmans M.
        • De Boeck K.
        Evaluation of dietary fiber intake in Belgian children with cystic fibrosis: Is there a link with gastrointestinal complaints?.
        J Pediatr Gastroenterol Nutr. 2002; 35: 610-614
        • Woestenenk J.W.
        • Schulkes D.A.
        • Schipper H.S.
        • van der Ent C.K.
        • Houwen R.H.J.
        Dietary intake and lipid profile in children and adolescents with cystic fibrosis.
        J Cyst Fibros. 2017; 16: 410-417
        • Ziai S.
        • Coriati A.
        • St-Pierre D.
        • et al.
        Glucose fluctuations are not modulated by the proportion of calories from macronutrients or spontaneous total energy expenditure in adults with cystic fibrosis.
        Can J Diabetes. 2016; 40: 389-392
        • Colombo C.
        • Bennato V.
        • Costantini D.
        • et al.
        Dietary and circulating polyunsaturated fatty acids in cystic fibrosis: Are they related to clinical outcomes?.
        J Pediatr Gastroenterol Nutr. 2006; 43: 660-665
        • Maqbool A.
        • Schall J.I.
        • Gallagher P.R.
        • Zemel B.S.
        • Strandvik B.
        • Stallings V.A.
        Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis.
        J Pediatr Gastroenterol Nutr. 2012; 55: 605-611
        • Moukarzel S.
        • Dyer R.A.
        • Innis S.M.
        Complex relation between diet and phospholipid fatty acids in children with cystic fibrosis.
        J Pediatr Gastroenterol Nutr. 2017; 64: 598-604
        • van der Doef H.P.J.
        • Kokke F.T.M.
        • Beek F.J.A.
        • Woestenenk J.W.
        • Froeling S.P.
        • Houwen R.H.J.
        Constipation in pediatric cystic fibrosis patients: An underestimated medical condition.
        J Cyst Fibros. 2010; 9: 59-63
        • World Health Organization
        Breastfeeding.
        (Published 2019. Accessed September 11, 2019)
        • Roesch E.A.
        • Nichols D.P.
        • Chmiel J.F.
        Inflammation in cystic fibrosis: An update.
        Pediatr Pulmonol. 2018; 53: S30-S50
        • Palmeira P.
        • Carneiro-Sampaio M.
        Immunology of breast milk.
        Rev Assoc Med Bras. 2016; 62: 584-593
        • Lai H.
        • Chin L.
        • Schoff S.
        • Zhang Z.
        • Greer F.R.
        Impact of breastfeeding on the nutritional status of infants with cystic fibrosis (CF) in the first year of life-results of the FIRST STUDY.
        FASEB J. 2016; 30 (672.674-672.674)
        • Colombo C.
        • Costantini D.
        • Zazzeron L.
        • et al.
        Benefits of breastfeeding in cystic fibrosis: A single-centre follow-up survey.
        Acta Paediatr. 2007; 96: 1228-1232
        • Parker E.M.
        • O'Sullivan B.P.
        • Shea J.C.
        • Regan M.M.
        • Freedman S.D.
        Survey of breast-feeding practices and outcomes in the cystic fibrosis population.
        Pediatr Pulmonol. 2004; 37: 362-367
        • Munck A.
        • Boulkedid R.
        • Weiss L.
        • et al.
        Nutritional status the first 2 years of life in cystic fibrosis diagnosed by newborn screening.
        J Pediatr Gastroenterol Nutr. 2018; 67: 123-130
        • Leung D.H.
        • Heltshe S.L.
        • Borowitz D.
        • et al.
        Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life.
        JAMA Pediatr. 2017; 171: 546-554
        • Jadin S.A.
        • Wu G.S.
        • Zhang Z.
        • et al.
        Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program.
        Am J Clin Nutr. 2011; 93: 1038-1047

      Biography

      C. M. McDonald is a clinical dietitian, Primary Children's Hospital, Salt Lake City, UT.

      Biography

      J. A. Alvarez is an assistant professor, Emory University School of Medicine, Atlanta, GA.

      Biography

      J. Bailey is a clinical dietitian, University of Alabama at Birmingham.

      Biography

      E. K. Bowser is an associate in pediatrics and a faculty nutritionist, Pediatric Pulmonary Division, University of Florida College of Medicine, Gainesville.

      Biography

      K. Farnham is a clinical pediatric dietitian, Nemours Children's Specialty Care, Jacksonville, FL.

      Biography

      M. Mangus is a patient advocate, San Antonio, TX.

      Biography

      L. Padula is an advanced practice dietitian, Children's Hospital of Philadelphia, Philadelphia, PA.

      Biography

      K. Porco is a patient advocate, Attain Health Foundation, Red Lodge, MT.

      Biography

      M. Rozga is a Nutrition Researcher, Academy of Nutrition and Dietetics, Evidence Analysis Center, Chicago, IL